News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Biologics are the next challenge for multinationals looking to enter the lucrative Chinese market, but such drugs must offer value and genuine innovation, say the CEOs of Merck KGaA and Chi-Med.
Valerion Therapeutics has inked an agreement for the manufacture of two orphan drug candidates using Catalent’s GPEx mammalian cell line platform.
Ranbaxy Laboratories has launched the monoclonal antibody Infimab, the first Remicade (Infliximab) biosimilar, in India -- which is the first what could be a few home-grown biosimilar launches.